Tech Company Financing Transactions
TORL BioTherapeutics Funding Round
TORL BioTherapeutics, based in Los Angeles, secured $158 million from Goldman Sachs, Alexandria Venture Investments and Bristol Myers Squibb.
Transaction Overview
Company Name
Announced On
4/13/2023
Transaction Type
Venture Equity
Amount
$158,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to to advance TORL-1-23, a first-in-class, clinical-stage ADC targeting Claudin 6, TORL-2-307, a clinical-stage ADC targeting Claudin 18.2 and other novel clinical and preclinical stage programs.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Los Angeles, CA Undisclosed
USA
Los Angeles, CA Undisclosed
USA
Phone
Undisclosed
Email Address
Not Recorded
Overview
TORL BioTherapeutics is a clinical-stage bi ©pharmaceutical business. Operator of a drug development company intended to accelerate pre-clinical drug discovery. The company offers combined UCLA's slamon drug screening with Caltech's Stoltz chemistry platform in order to identify targets with clinical success, enabling researchers to develop proprietary drugs with unique and optimized profiles.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Licata
Co-Founder
Mark Alles
Co-Founder
Dennis Slamon
Browse more venture capital transactions:
Prev: 4/13/2023: Thynk.Cloud venture capital transaction
Next: 4/13/2023: Natix venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record tech company VC transactions. VC transactions reported here are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs